View on Pubmed.gov 25729364 | View on doi.org 10.3389/fphar.2... | View the free full text Full text
Advantages and applications of CAR-expressing natural killer cells.
- Institute of Cellular Therapeutics Integrated Research and Treatment Center Transplantation, Hannover Medical School Hannover, Germany.
- Institute of Experimental Hematology, Hannover Medical School Hannover, Germany.
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy Frankfurt am Main, Germany.
Abstract
In contrast to donor T cells, natural killer (NK) cells are known to mediate anti-cancer effects without the risk of inducing graft-versus-host disease (GvHD). In order to improve cytotoxicity against resistant cancer cells, auspicious efforts have been made with chimeric antigen receptor (CAR) expressing T- and NK cells. These CAR-modified cells express antigen receptors against tumor-associated surface antigens, thus redirecting the effector cells and enhancing tumor-specific immunosurveillance. However, many cancer antigens are also expressed on healthy tissues, potentially leading to off tumor/on target toxicity by CAR-engineered cells. In order to control such potentially severe side effects, the insertion of suicide genes into CAR-modified effectors can provide a means for efficient depletion of these cells. While CAR-expressing T cells have entered successfully clinical trials, experience with CAR-engineered NK cells is mainly restricted to pre-clinical investigations and predominantly to NK cell lines. In this review we summarize the data on CAR expressing NK cells focusing on the possible advantage using these short-lived effector cells and discuss the necessity of suicide switches. Furthermore, we address the compliance of such modified NK cells with regulatory requirements as a new field in cellular immunotherapy.
References
PLoS One. 2011;6(11):e27351
Mol Ther. 2014 Sep;22(9):1564-74
Blood. 2009 Jun 11;113(24):6094-101
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):261-6
Cited by 247 citations (total)
Journal Article
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
Electronic publication date October 25, 2017
K H Chen [...] Y Ma et al.
The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy...
Journal Article
Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.
Electronic publication date December 26, 2017
Martin Felices [...] Daniel A Vallera et al.
Cancer immunotherapies have gained significant momentum over the past decade, particularly with the advent of checkpoint inhibitors and CAR T-cells....
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •